Sanofi Pasteur’s Quadracel vaccine receives FDA approval

Sanofi Pasteur, the vaccines division of Sanofi, announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved use of Quadracela (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV) vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age. "The FDA approval of ["]